Navigation Links
ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program
Date:2/26/2009

OSLO, Norway, February 26 /PRNewswire/ -- ScreenCancer AS, a Norwegian company offering cancer screening management services to employers, insurance companies and individuals, today announced that it has added the InSure(R) FIT(TM) take-at-home colorectal cancer screening test to its European Cancer Screening Program. The company's two-year distribution agreement with Enterix Inc., a subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), the world leader in diagnostic testing, information and services, grants ScreenCancer limited exclusive rights to offer InSure FIT in 24 countries of the European Economic Union, including France, Germany and the U.K.

Colon cancer is the second most common form of cancer in Europe. In 2004, 376,400 people contracted the illness while 203,700 colon cancer patients died. Despite considerable progress in treatment, the mortality rate in Europe has remained high and it has been concluded that it can only be reduced through an intensive campaign of prevention and screening.[1][2] Medical experts recommend annual screening for all patients over age 50 at average risk, younger for those at higher risk.

"We are pleased to provide annual colorectal cancer screening with InSure FIT to our customers," said Christian Horn, CEO of ScreenCancer. "Colorectal cancer is often treatable and even preventable when caught early, which is why annual screening with the InSure FIT test is so important. The test has been shown to be highly effective in helping to detect colorectal cancers earlier, and, we believe, is the easiest test for patients to use, making it an important component of our program designed to increase screening rates for the major cancers."

InSure FIT features a unique long-handled blue brush to collect two water-based samples - rather than the solid samples required by other FITs (fecal immunochemical tests) or FOBTs (fecal occult blood tests) - and does not require any change in patient diet or medication. In one study, patients were 66% more compliant in completing their InSure FIT test compared to a leading guaiac-based FOBT test.[3] Information about the InSure FIT test is available at http://www.doyouhavetheguts.com.

A recent interim study conducted at the Flinders Centre for Innovation in Cancer (Australia) and presented at the annual Digestive Disease Week Conference in May 2008 found that, in patients with a family or personal history of colorectal cancer or adenoma who completed an annual FIT, detection of cancerous lesions occurred an average of 26.5 months earlier than would have occurred during the three- or five-year study-required colonoscopy alone. Detection of precancerous lesions in this group occurred 18.4 months earlier.[4]

"Quest Diagnostics is committed to expanding the number of people getting screened annually for colorectal cancer, and ScreenCancer is a valued partner in that endeavor," remarked Paul Rust, Quest Diagnostics' Vice President, Point of Care Testing. "ScreenCancer's introduction of an innovative, comprehensive cancer screening program in the European commercial market, combined with tests such as the InSure FIT colorectal cancer screening test, promise to help improve cancer screening rates, and as a result, through early detection, help save lives."

About ScreenCancer, AS

ScreenCancer AS provides cancer screening management services to self-insured employers and individuals. ScreenCancer offers a private alternative where little or no public cancer screening program exists. With a panel of the leading screening tests for several major cancers, and clinical follow-up by experts in the field, ScreenCancer provides a method for employers and individuals to help reduce the risk and negative effects of cancer. For more information, please visit the company's web site at http://www.screencancer.com.

    ---------------------------------

    [1] Classen, Lambert, "Colorectal Cancer Screening in Europe, a Survey of
        the International Digestive Disease Alliance between November 2004
        and March, 2007"

    [2] Boyle, P., Ferlay, J., "Cancer incidence and mortality in Europe. Ann
        Onco 2005; 16: 481-488

    [3] Cole SR, Young GP, Esterman A, Cadd A, Morcom J. A randomised trial
        of the impact of new faecal haemoglobin test technologies on
        population participation in screening for colorectal cancer. J Med
        Screen 2003;10:117-122.

    [4] The study abstract is published in the April 2008 supplement of
        Gastroenterology


    For more information contact:
    Christian Horn, CEO,
    Phone: +47-90163153,
    Christian.horn@screencancer.com .


'/>"/>
SOURCE ScreenCancer AS
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. New Colorectal Module From Simbionix Advances Laparoscopic Cancer Treatment
5. GeneNews appoints Canadian Colorectal Cancer Advisory Board
6. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
7. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. GeneNews launches worlds first blood test for colorectal cancer screening
10. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
11. Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of ... lumbar disc production, company President, Jake Lubinski will be traveling to Germany on ... disc in Cologne and Karlsruhe to discuss the benefits of a viscoelastic total ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016  In five ... of Hematology (ASH) Annual Meeting and Exposition in ... biomedical engineering methods to improve the delivery of life-saving ... These new methods are designed to carry therapies directly ... needed most, which could provide a substantial advantage over ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):